CommentSurgery versus SABR for early-stage lung cancer—time to call it a draw?
References (10)
- et al.
Failed randomized clinical trials in radiation oncology: what can we learn?
Int J Radiat Oncol Biol Phys
(2018) Do we know bad science when we see it?
J Thorac Cardiovasc Surg
(2015)- et al.
Stereotactic ablative radiation therapy versus surgery in early lung cancer: a meta-analysis of propensity score studies
Int J Radiat Oncol Biol Phys
(2018) - et al.
Non-inferiority cancer clinical trials: scope and purposes underlying their design
Ann Oncol
(2013) - et al.
Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: a systematic review
J Thorac Oncol
(2019)
Cited by (5)
Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer – A Done Deal?
2022, Clinical OncologyCitation Excerpt :Subsequently, the STARS trial was revised with re-accrual of the SABR arm to a larger sample size, which was then compared to a propensity-matched surgically managed cohort [21]. This is well-described in another recent review article [22]. The median follow-up was 5.1 years and survival outcomes were similar between the SABR and surgery group [21].
Cytofluorometric assessment of cell cycle progression in irradiated cells
2022, Methods in Cell BiologyCitation Excerpt :Radiation therapy (RT) is one of the regimens most commonly employed in modern clinical cancer care, either as a curative intervention (e.g., in patients with early-stage prostate cancer) (Harmenberg et al., 2011; Nakano et al., 2010), or to palliate symptoms from metastatic disease (e.g., pain) (Spencer et al., 2018). Technological progress achieved over the past two decades has enabled the delivery of high RT doses to ever more precise target volumes along with minimal exposure of normal tissues, considerably expanding the clinical applications or RT (Citrin, 2017; Deutsch et al., 2019; Louie et al., 2021; Salama et al., 2012; Siva et al., 2017; Zaorsky et al., 2013). RT largely operates by directly or indirectly (via reactive oxygen species) (Li et al., 2021a; Renaudin, 2021) causing damage to macromolecules, including DNA (Pilié et al., 2019) and lipids (Lei et al., 2020; Ye et al., 2020).
Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum
2024, Current Oncology ReportsMicrowave ablation for the treatment of peripheral ground-glass nodule-like lung cancer: Long-term results from a multi-center study
2023, Journal of Cancer Research and Therapeutics